A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study
- PMID: 35714658
- PMCID: PMC9197249
- DOI: 10.1016/S2213-2600(22)00169-2
A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study
Abstract
Health consequences that persist beyond the acute infection phase of COVID-19, termed post-COVID-19 condition (also commonly known as long COVID), vary widely and represent a growing global health challenge. Research on post-COVID-19 condition is expanding but, at present, no agreement exists on the health outcomes that should be measured in people living with the condition. To address this gap, we conducted an international consensus study, which included a comprehensive literature review and classification of outcomes for post-COVID-19 condition that informed a two-round online modified Delphi process followed by an online consensus meeting to finalise the core outcome set (COS). 1535 participants from 71 countries were involved, with 1148 individuals participating in both Delphi rounds. Eleven outcomes achieved consensus for inclusion in the final COS: fatigue; pain; post-exertion symptoms; work or occupational and study changes; survival; and functioning, symptoms, and conditions for each of cardiovascular, respiratory, nervous system, cognitive, mental health, and physical outcomes. Recovery was included a priori because it was a relevant outcome that was part of a previously published COS on COVID-19. The next step in this COS development exercise will be to establish the instruments that are most appropriate to measure these core outcomes. This international consensus-based COS should provide a framework for standardised assessment of adults with post-COVID-19 condition, aimed at facilitating clinical care and research worldwide.
Copyright © 2022 World Health Organization. Published by Elsevier Ltd. All rights reserved. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests DM is a co-chair of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric Long COVID working group and a member of the ISARIC working group on long-term follow-up in adults. CA reports grants or contracts from Dr Wolff Group, Bionorica, and The European Cooperation in Science and Technology; consulting fees from the Dr Wolff Group, Bionorica, and Sanofi-Aventis Germany; and honoraria from AstraZeneca. SLG is the project coordinator of the Core Outcome Measures in Effectiveness Trials (COMET) Initiative. PRW is chair of the COMET Management Group. All other authors declare no competing interests.
Figures
Comment in
-
Post-COVID-19 condition in children: a COS is urgently needed.Lancet Respir Med. 2022 Jul;10(7):628-629. doi: 10.1016/S2213-2600(22)00211-9. Epub 2022 Jun 14. Lancet Respir Med. 2022. PMID: 35714657 Free PMC article. No abstract available.
-
The COVID-19 continuum of illness.Lancet Respir Med. 2022 Jul;10(7):630-631. doi: 10.1016/S2213-2600(22)00219-3. Epub 2022 Jun 15. Lancet Respir Med. 2022. PMID: 35716674 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
